
News|Articles|April 1, 2002
Rosuvastatin: A new HMG0CoA reductase inhibitor for hypercholesterolemia (PDF)
Rosuvastatin is an investigational HMG-CoA reductase inhibitor expected to gain FDA approval later this year for treatment of hypercholesterolemia. It has significantly exceeded atorvastatin, pravastatin, and simvastatin in reducing LDL cholesterol in clinical trials. This Focus article reviews those trials as well as rosuvastatin's pharmacologic and safety profiles in an effort to delineate its likely role in cholesterol-reducing therapy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Beyond Sotyktu: Next-Gen TYK2 Drugs Enter Late-Stage Development | Fall Clinical Derm 2025
2
Almost Half of Severe Alopecia Areata Pediatric Patients Saw Hair Regrowth on Olumiant, Study Shows | 2025 Fall Clinical Derm
3
When It Comes to Interleukins and Atopic Dermatitis,13 Is a Lucky Number |Fall Clinical Derm 2025
4
MHE Week in Review – AAO 2025 Highlights
5


















































